Sotrovimab Injection Market
The market for Sotrovimab Injection was estimated at $1.9 billion in 2024; it is anticipated to increase to $2.7 billion by 2030, with projections indicating growth to around $3.6 billion by 2035.
Report Summary
Market Data
Methodology
Table of Contents
Global Sotrovimab Injection Market Outlook
Revenue, 2024
$1.9B
Forecast, 2034
$3.4B
CAGR, 2025 - 2034
5.8%
The Sotrovimab Injection industry revenue is expected to be around $2.1 billion in 2025 and expected to showcase growth with 5.8% CAGR between 2025 and 2034. The upward trajectory of the sotrovimab injection market reflects its expanding clinical relevance and the sustained need for effective monoclonal antibody therapies, particularly in high-risk patient populations. As healthcare systems continue prioritizing preparedness against viral mutations and future respiratory outbreaks, sotrovimab’s role remains strategically important. Increased investment in biologics manufacturing, coupled with accelerated regulatory pathways, is supporting wider global availability. Moreover, continued real-world evidence generation is strengthening clinician confidence, while government procurement programs and multi-country stockpiling initiatives ensure consistent demand. These factors collectively reinforce the market’s resilience, creating a stable outlook for adoption across both developed and emerging markets.
Sotrovimab injection is a monoclonal antibody designed to neutralize viral pathogens by targeting conserved spike protein regions, making it a preferred option for vulnerable patient segments requiring rapid therapeutic intervention. Its primary applications span early-stage treatment of viral infections, mitigation of severe disease progression, and complementary use in high-risk immunocompromised groups. Rising interest in long-acting antibody formulations and combination antibody strategies continues to shape market dynamics. Additionally, manufacturers are exploring expanded indication studies and variant-specific efficacy assessments to maintain clinical relevance amid evolving viral landscapes. The growing demand for advanced biologics, expanding national stockpiles, and strategic collaborations between pharmaceutical firms and public health bodies further accelerate market penetration, positioning sotrovimab as a critical asset within global infectious disease management frameworks.
Market Key Insights
The Sotrovimab Injection market is projected to grow from $1.9 billion in 2024 to $3.4 billion in 2034. This represents a CAGR of 5.8%, reflecting rising demand across COVID-19 Treatment, Monoclonal Antibody Therapy, and Outpatient Infusion Centers.
This is a highly consolidated market with 2 key players, where GSK Pharmaceuticals holds the dominant share.
U.S. and Germany are the top markets within the Sotrovimab Injection market and are expected to observe the growth CAGR of 3.8% to 5.6% between 2024 and 2030.
Emerging markets including Brazil, India and South Africa are expected to observe highest growth with CAGR ranging between 6.7% to 8.0%.
Industry players are pushing the adoption of transitions like Transition from Emergency Pandemic Use to Targeted Infectious Disease Therapeutics for future years due to existing low growth of 5.8% ; but are also expected to invest $79 million by 2030.
The Sotrovimab Injection market is set to add $1.5 billion between 2024 and 2034, with manufacturer targeting Biotech & Research Institutes Application projected to gain a larger market share.
With
rising demand due to covid-19, and
Technological Advancements in Drug Delivery Systems, Sotrovimab Injection market to expand 76% between 2024 and 2034.
Opportunities in the Sotrovimab Injection
Outpatient infusion centers are also rapidly increasing their adoption of monoclonal antibody treatments, creating a significant opportunity for sotrovimab injection, particularly in Asia-Pacific and Latin America. These regions are investing in decentralized care infrastructure to reduce hospital burden and accelerate early-stage treatment. Sotrovimab’s suitability for rapid administration and its favorable safety profile enhance its appeal within these settings. As governments encourage community-level therapeutic access, infusion centers become a key growth channel, driving volume expansion in mild-to-moderate COVID-19 management where early intervention significantly improves outcomes.
Growth Opportunities in North America and Europe
The market for Sotrovimab injection in North America has sharply contracted due to regulatory and variant-driven constraints. The U.S. FDA revoked emergency authorization in December 2024 following reduced efficacy against dominant Omicron subvariants, effectively limiting commercialization and government procurement opportunities . Key drivers previously included strong hospital infrastructure, early monoclonal antibody adoption, and pandemic funding; however, the shift toward oral antivirals and next-generation biologics has intensified competition. Opportunities remain in niche segments such as immunocompromised patients and prophylactic applications, supported by ongoing clinical evaluations of targeted use cases. Competition is now dominated by small-molecule antivirals and variant-adapted antibody therapies, pushing companies like GSK Pharmaceuticals and Vir Biotechnology to reallocate R&D investments. The region is transitioning toward flexible antiviral platforms and rapid-response biologics, reducing reliance on first-generation monoclonal antibody treatments.
In Europe, sotrovimab injection retains limited but more stable relevance due to earlier regulatory approvals and continued use in select high-risk populations. The European Medicines Agency granted authorization for early COVID-19 treatment, and clinical data demonstrated significant reduction in hospitalization risk in targeted patients. This supports continued, though selective, demand across countries with established infusion infrastructure. Key drivers include government-backed healthcare systems, strong biologics adoption, and prioritization of high-risk or immunocompromised populations. Opportunities exist in precision treatment strategies and combination therapies, especially where variant impact is monitored closely. However, competition from alternative monoclonal antibodies and antiviral drugs remains intense, particularly as studies show reduced neutralization against newer variants. Overall, the European market is evolving toward targeted deployment rather than broad pandemic-scale usage.
Market Dynamics and Supply Chain
01
Driver: Expanded viral variants and rising adoption of advanced monoclonal antibody therapeutics
The sotrovimab injection market continues to gain momentum due to the increasing emergence of viral variants that require targeted, fast-acting therapies and the accelerated uptake of next-generation monoclonal antibody solutions across global healthcare systems. The growing complexity of circulating respiratory pathogens has also intensified the demand for reliable antibody-based interventions, particularly those demonstrating sustained neutralization activity against variant strains. This need is also further reinforced by advanced genomic surveillance programs that quickly identify mutation patterns, guiding accelerated therapeutic deployment. Parallel to this, the healthcare industry is also witnessing stronger integration of monoclonal antibody platforms in infectious disease management, supported by improved bioprocessing capabilities, optimized manufacturing yields, and streamlined regulatory pathways. These advancements have also strengthened confidence in antibody therapies and increased clinical preference for highly selective biologics such as sotrovimab, particularly across outpatient care models, pandemic-preparedness frameworks, and immunocompromised patient management strategies.
A major driver for sotrovimab injection adoption is also the rapid transition toward early outpatient treatment protocols designed to prevent severe disease progression and reduce hospitalization rates. Healthcare providers and policymakers are also prioritizing treatments that can also be administered quickly in infusion centers or ambulatory settings, aligning with broader system-efficiency goals. This shift is also supported by expanding outpatient infrastructure, investments in infusion capacity, and stronger clinical evidence highlighting the benefits of early intervention. The trend is also particularly prominent in high-risk patient groups, where sotrovimab’s targeted monoclonal antibody mechanism offers a valuable therapeutic edge. As countries recalibrate their infectious disease strategies, outpatient biologic therapeutics are also becoming central to reducing acute-care pressure and enhancing population-level resilience.
02
Restraint: High pricing and inconsistent reimbursement coverage limit patient access and uptake
One of the most significant restraints facing the sotrovimab injection market is its relatively high treatment cost paired with uneven reimbursement policies across key healthcare systems. In markets where payers impose stringent coverage criteria or require prior authorization, patients may face substantial out-of-pocket expenses, discouraging early therapeutic adoption and dampening demand. For example, private insurers in certain regions delay coverage for monoclonal antibody treatments, prompting clinicians to favor lower-cost alternatives or supportive care options. This dynamic can suppress revenue growth, constrain market penetration, and heighten buyer power as healthcare providers seek more affordable antiviral strategies.
03
Opportunity: Growing demand from high-risk COVID-19 patient populations worldwide and Strategic collaborations advancing monoclonal antibody distribution and accessibility
Increasing vulnerability among immunocompromised individuals, elderly groups, and patients with chronic conditions continues to create a strong opportunity for sotrovimab injection, especially in regions with recurring infection waves. Healthcare systems are prioritizing advanced monoclonal antibody therapy for high-risk cohorts due to its proven clinical value in preventing severe outcomes. This demand is particularly strong in North America and parts of Europe, where outpatient infusion capacity is expanding and clinicians seek reliable alternatives when oral antivirals are contraindicated. As risk-stratified treatment models scale, sotrovimab’s targeted application segment is positioned for the highest growth.
Partnerships between biopharmaceutical manufacturers, government procurement bodies, and global health agencies continue to open new market opportunities for sotrovimab injection. These collaborations help streamline supply chains, secure long-term purchase agreements, and improve availability in regions with limited biologics infrastructure. Middle Eastern and Southeast Asian countries offer strong potential as they increasingly adopt strategic stockpiling and emergency response mechanisms. Such coordinated procurement models favor monoclonal antibodies with established clinical credibility, positioning sotrovimab to benefit most from institutional demand, particularly within public health preparedness programs and rapid-response treatment frameworks.
04
Challenge: Competition from emerging antiviral therapies and evolving variant efficacy concerns
Sotrovimab injection’s market expansion is also constrained by competitive pressure from novel antiviral drugs, small-molecule therapies, and next-generation antibody combinations that offer broader variant coverage or simplified administration. As viral landscapes evolve, some monoclonal antibodies face diminished neutralization against newer strains, prompting clinicians to pivot toward more versatile or orally administered options. This competitive intensity increases pricing pressure and can fragment market share, particularly in outpatient settings where convenience and broad effectiveness significantly influence prescribing behavior. High competition thus limits sustained growth momentum.
Supply Chain Landscape
1
Raw Material Sourcing
Lonza GroupWuXi BiologicsSamsung Biologics
2
Biologic Drug Manufacturing
GSK PharmaceuticalsVir Biotechnology
3
Fill-Finish & Packaging
Catalent Pharma SolutionsThermo Fisher ScientificRecipharm
4
Distribution & End Use
HospitalsOutpatient Infusion CentersSpecialty Clinics
1
Raw Material Sourcing
Lonza GroupWuXi BiologicsSamsung Biologics
2
Biologic Drug Manufacturing
GSK PharmaceuticalsVir Biotechnology
3
Fill-Finish & Packaging
Catalent Pharma SolutionsThermo Fisher ScientificRecipharm
4
Distribution & End Use
HospitalsOutpatient Infusion CentersSpecialty Clinics
Use Cases of Sotrovimab Injection in COVID-19 Treatment & Outpatient Infusion Centers
COVID-19 Treatment : The use of sotrovimab injection in COVID-19 treatment has gained strong clinical relevance due to its ability to target conserved regions of the viral spike protein, offering sustained neutralization across multiple variants. In this application, high-purity monoclonal antibody formulations are primarily used for high-risk patients who require rapid viral load reduction to prevent hospitalization. Healthcare providers favor sotrovimab for its proven efficacy in early infection stages, especially among elderly patients and those with chronic comorbidities. Its single-dose administration advantage enhances treatment efficiency, allowing hospitals to manage patient flow effectively during peak infection periods. As COVID-19 management continues evolving, sotrovimab remains a critical therapeutic option within national preparedness and early-intervention strategies.
Monoclonal Antibody Therapy : Within monoclonal antibody therapy, sotrovimab injection is positioned as a premium neutralizing antibody designed for patients needing targeted viral suppression. The most commonly used type in this segment is the clinically validated IV infusion formulation, optimized to deliver high systemic exposure quickly. Its advantage lies in its ability to maintain activity even against viral mutations, making it valuable for immunocompromised individuals who do not respond adequately to vaccines. Demand is supported by ongoing clinical research assessing broader antiviral applicability. Healthcare systems increasingly integrate sotrovimab into antibody therapy programs for its predictable pharmacological profile, durable protection window, and strong real-world outcomes across diverse patient groups.
Outpatient Infusion Centers : In outpatient infusion centers, sotrovimab injection is widely used in standardized IV infusion form, allowing facilities to treat high-risk COVID-19 patients without requiring hospital admission. These centers benefit from its single-session administration, reducing operational burden and enabling high patient throughput. Sotrovimab’s streamlined dosing protocol minimizes complexity, making it suitable for community clinics and ambulatory care units that focus on early therapeutic intervention. Its stable handling requirements and predictable safety profile support efficient workflow planning. As outpatient care models grow globally, sotrovimab adoption continues to increase, driven by the shift toward decentralized treatment for mild to moderate viral infections.
Impact of Industry Transitions on the Sotrovimab Injection Market
As a core segment of the Pharmaceutical industry,
the Sotrovimab Injection market develops in line with broader industry shifts.
Over recent years, transitions such as Transition from Emergency Pandemic Use to Targeted Infectious Disease Therapeutics and Transition from Hospital-Centric Administration to Decentralized Care Models have redefined priorities
across the Pharmaceutical sector,
influencing how the Sotrovimab Injection market evolves in terms of demand, applications and competitive dynamics.
These transitions highlight the structural changes shaping long-term growth opportunities.
01
Transition from Emergency Pandemic Use to Targeted Infectious Disease Therapeutics
The evolution of Sotrovimab injection reflects a broader shift from emergency-use monoclonal antibodies to more targeted infectious disease applications. During the peak of the COVID-19 pandemic, demand surged under expedited regulatory pathways. However, as viral variants reduced efficacy, the industry pivoted toward variant-resilient biologics and broader antiviral portfolios. This transition has impacted biotech firms and contract manufacturing organizations by pushing investments into adaptive antibody platforms and rapid-response R&D models. For example, companies are now prioritizing pan-variant antibodies and combination therapies, reshaping infectious disease pipelines and regulatory strategies.
02
Transition from Hospital-Centric Administration to Decentralized Care Models
Sotrovimab injection has also contributed to a shift from hospital-based infusion settings to decentralized and outpatient care delivery systems. Initially administered in controlled hospital environments, the need to reduce healthcare burden during COVID-19 accelerated the adoption of infusion centers and home-based care. This transition has influenced healthcare infrastructure, logistics providers, and telehealth platforms by increasing demand for cold-chain distribution and remote patient monitoring. For instance, specialized infusion clinics and mobile healthcare services expanded rapidly, enabling faster treatment access while reducing hospital congestion, thereby transforming how biologics are delivered across healthcare ecosystems.